Reported 2 months ago
As the demand for GLP-1 weight-loss drugs elevates the biotech sector, analysts emphasize that there are still overlooked investment opportunities. Goldman Sachs analyst Salveen Richter highlights companies like Amgen and Vertex, which are innovating beyond weight loss into cancer and autoimmune disease treatments, as promising options for investors looking for growth and stability.
Source: YAHOO